|
|
| | Dihydroergotoxine mesylate Basic information |
| Product Name: | Dihydroergotoxine mesylate | | Synonyms: | cck179;co-dergocrinemesylate;dihydroergotoxinemesilate;dihydroergotoxinemethanesulfonate;dihydroergotoxinemethanesulphonate;dihydroergotoxinemonomethanesulfonate(salt);dihydroergotoxinmesylate;dihydroergotoxinmethanesulfonate | | CAS: | 8067-24-1 | | MF: | C20H29N3O5S | | MW: | 423.53 | | EINECS: | | | Product Categories: | | | Mol File: | 8067-24-1.mol |  |
| | Dihydroergotoxine mesylate Chemical Properties |
| storage temp. | Store at RT | | form | neat |
| Hazard Codes | T | | Risk Statements | 60 | | Safety Statements | 53-36/37/39-45 | | RIDADR | 1544 | | RTECS | KE8800000 | | HazardClass | 6.1(b) | | PackingGroup | III | | HS Code | 3003490000 |
| | Dihydroergotoxine mesylate Usage And Synthesis |
| Description | Ergoloid is a mixture of the ergot alkaloids dihydroergocornine, dihydroergocrystine, and dihydroergocryptine. It blocks reflex vasodilation and vasoconstriction induced by norepinephrine in dogs when injected into the kidney at a dose of 0.15 mg. Ergoloid blocks norepinephrine-induced cAMP production in rat brain cortical homogenates ex vivo in a dose-dependent manner. It also acts as an erectogenic agent in rats. Formulations containing ergoloid have been used in the treatment of migraine headaches and vascular dementias. | | Uses | Cognition adjuvant. | | Definition | ChEBI: A mixture of hydrogenated ergot alkaloids consisting of the methanesulfonic acid salts of dihydroergocornine (R = CHMe2), dihydroergocristine (R = CH2Ph), and alpha- and beta-dihydroer
ocryptine (R = CH2CHMe2 and CH(Me)Et, respectively). It is used for the symptomatic treatment of mild to moderate dementia in the elderly, although its value is not established. | | Brand name | Alkergot (Sandoz); Circanol(3M Pharmaceuticals); Deapril (Bristol-Myers Squibb);Gerimal (Watson); Hydergine (Novartis). | | Pharmacology | The metabolic effects of ergoloid mesylates (Hydergine) may include enhancement of noradrenergic, dopaminergic and serotoninergic neurotransmission (Weil,1988) and reduction of free radicals. Schneider and Olin (1994) reviewed 151 reports on the use of Hydergine in senile dementia, but only 47 of these trials (31%) met strict criteria for meta-analysis. ACochrane review (Olin et al., 2001) confirmed that patients with VaD appeared to benefit more than patients with AD in terms of cognition,clinical global ratings and combined measures. However, compared with placebo, efficacy was very modest. Thus, there are no grounds to recommend its use. |
| | Dihydroergotoxine mesylate Preparation Products And Raw materials |
|